The Access to Medicine Foundation recently released the seventh Access to Medicine Index (ATMI), which ranks 20 pharmaceutical companies on how they’re making medicines and vaccines accessible to people in 106 low- and middle-income countries.
This year’s index ranks GlaxoSmithKline, Novartis, Johnson & Johnson, Pfizer and Sanofi as the top five companies improving access to medicine. The index also notes that more than half of companies’ research and development is focused on HIV, AIDS, tuberculosis, malaria and now COVID-19. Cancer accounts for more than two-thirds of non-communicable disease projects for the companies.
Mercy Investment Services has a long history of working with the ATMI on the issue of access to medicines in low- and middle-income countries. Currently, Mercy engages 12 of the 19 companies on the index, including all of the U.S. companies, and regularly uses the scores to measure progress over time and benchmark where companies should be on significant issues. Mercy will continue to use this tool in our ongoing efforts to advocate for equitable access to health care.